Mar 27 |
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
|
Mar 27 |
Precision BioSciences GAAP EPS of -$4.06 misses by $2.03, revenue of $7.04M misses by $7.42M
|
Mar 27 |
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
|
Mar 27 |
Earnings Scheduled For March 27, 2024
|
Mar 26 |
Precision BioSciences Q4 Earnings Preview
|
Mar 20 |
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
|
Mar 19 |
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
|
Mar 6 |
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
|
Mar 1 |
Precision BioSciences stock falls after pricing $40M securities offering
|
Mar 1 |
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
|